青痤乳膏的药效学实验研究

目的：评价青痤乳膏治疗痤疮的作用机制及药效学研究。方法：采用小鼠二甲苯耳肿胀法、豚鼠磷酸组织胺法、小鼠耳部奇正消痛贴微循环实验法以观察青痤乳膏的药效学机制。结果：青痤乳膏能够明显抑制二甲苯所致小鼠耳片炎性肿胀、提高了磷酸组织胺对豚鼠右后足背部的致痒阈、改善了奇正消痛贴对小鼠耳廓微循环。结论：青痤乳膏具有较好的改善微循环、抗炎、止痒作用。     

超脉冲CO2点阵激光联合胶原贴敷料治疗面部痤疮瘢痕疗效观察

目的 探讨超脉冲CO2点阵激光联合胶原贴敷料治疗面部痤疮瘢痕的临床效果.方法 选取2020年1月至2021年1月宜阳县人民医院收治的60例面部痤疮瘢痕患者作为研究对象,并按照随机数表法将其随机分为观察组和对照组,每组30例,观察组患者采用超脉冲CO2点阵激光联合胶原贴敷料治疗,对照组患者单纯采用超脉冲CO2点阵激光治疗...     

HPLC-PDA检测祛痘除螨类化妆品中非法添加盐酸米诺环素方法的建立

目的建立用高效液相色谱-二极管阵列检测法（HPLC-PDA）检测祛痘除螨类化妆品中非法添加的盐酸米诺环素,以打击化妆品中非法添加禁限物质的不法行为。方法采用Waters Symmetry C18（5μm,4.6 mm×250 mm）色谱柱;以醋酸铵缓冲盐溶液（取醋酸铵15 g、氯化钾10 g与乙二胺四乙酸二钠5 g,加水溶解并稀释成1 000 ml）-乙腈（70∶30）为流动相等度洗脱;流速为1.0 ml/min;柱温为25℃;检测波长280 nm;用PDA检测,以保留时间和紫外光谱图定性,峰面积定量。结果盐酸米诺环素在1~100μg/ml范围内与峰面积呈良好的线性关系,相关系数为1.000 0,检出限为0.1μg/ml,方法的回收率为88.5%~98.5%,RSD为1.0%~1.5%（n=6）。结论该方法特异性强,灵敏度高,准确可靠,适用于不同基质样品中盐酸米诺环素的检测。     

女性痤疮患者血清中性激素水平的研究

目的　探讨女性痤疮患者体内性激素水平的改变。方法　采用对照研究的方法对 5 0例女性痤疮患者和 15名正常对照者血清中睾酮 (T) 游离睾酮 (FT) 雌二醇 (E2 ) 性激素结合球蛋白 (SHBG)水平进行了测定。结果　女性痤疮患者的血清中FT水平明显高于正常对照组 (P <0 0 5 ) ,E2 和SHBG水平低于正常组 (P <0 0 5 ) ,伴多毛或月经异常的女性痤疮患者血清中T明显高于正常对照组 (P <0 0 5 )。女性痤疮的严重程度与性激素水平无显著关联 患者体重指数与对照组差异无显著性 (P >0 0 5 )。结论　性激素尤其是游离睾酮在女性痤疮发病中起了一定的作用。     

中西医综合疗法治疗重度寻常痤疮的疗效观察

目的:探讨综合疗法治疗重度寻常痤疮的临床效果。方法:33例门诊病人随意分为两组,治疗组23例,采用中西医综合疗法;对照组10例,单纯西药治疗。4周为一疗程,观察临床疗效。结果:综合治疗组与对照组的总有效率分别为91.3%和80%,两者比较无显著性差异(P<0.05)。结论:说明辩证与辩病结合,内服与外用并举的综合疗法治疗重度寻常痤疮有较好的疗效。     

围刺结合刺络拔罐治疗聚合性痤疮的随机对照研究

目的:观察围刺结合刺络拔罐治疗聚合性痤疮的临床疗效,探讨其机制。方法:选取52例聚合性痤疮患者,随机分为针刺组和西药组各26例。针刺组取痤疮局部围刺的基础上,合谷、血海、丰隆、三阴交穴常规针刺,每日治疗1次,同时,结合大椎、肺俞穴刺络拔罐,每周治疗2次;西药组选用异维A酸胶丸口服,10mg/次,每日3次;两组疗程均为4周。治疗结束后观察两组的临床疗效,并于治疗前后分别釆用双抗体夹心ELISA法检测血清白介素-6(IL-6)含量。结果:针刺组26例中,痊愈3例,显效14例,有效6例,无效3例,总有效率为88.5%;西药组26例中,痊愈4例,显效11例,有效7例,无效4例,总有效率84.6%;两组临床疗效比较,差异无统计学意义(P>0.05)。两组治疗后血清IL-6水平较治疗前均明显下降(P<0.01),针刺组较西药组降低更明显(P<0.05)。西药组与针刺组比较有更为明显的不良反应。结论:围刺结合刺络拔罐治疗聚合性痤疮疗效显著,与西药疗效相当;降低血清IL-6水平,调节机体的免疫功能,可能是其促进皮损恢复的机制之一。     

The Safety of Isotretinoin Treatment in Patients with Peanut Allergies

BackgroundIsotretinoin, the gold standard treatment for nodulocystic acne vulgaris, is contraindicated in patients with a soy allergy. Due to potential cross-reactivity, a history of peanut allergy is listed as a contraindication to isotretinoin use in some countries.ObjectiveWe sought to further evaluate the safety of isotretinoin use in patients with peanut allergy.MethodsUsing Epic’s SlicerDicer, patients were identified with both an allergy to peanuts and history of isotretinoin use for treatment of acne vulgaris. Clinical manifestation to peanut exposure, peanut-specific skin prick and/or IgE testing, and adverse reactions to isotretinoin use were recorded via chart review and phone interviews.ResultsTen patients were identified having both a peanut allergy and treatment for acne vulgaris with isotretinoin. All patients tolerated isotretinoin without evidence of allergy.ConclusionIsotretinoin use did not result in allergic eruptions in patients with a known peanut allergy, however, more robust clinical studies are needed to confirm the extent of its use in this patient population.     

Oral Zinc as a Novel Adjuvant and Sparing Therapy for Systemic Isotretinoin in Acne Vulgaris: A Preliminary Comparative Study

BackgroundSystemic isotretinoin is the most effective treatment for acne vulgaris (AV). However, numerous side effects are associated with isotretinoin. Oral zinc has a better safety profile and has been used to treat AV with variable results. ObjectiveWe sought to evaluate the safety and efficacy of combining oral zinc to low-dose systemic isotretinoin in AV patients.MethodsSixty AV patients were divided into two groups. Group A received oral zinc sulfate plus low-dose isotretinoin and Group B received the standard isotretinoin dosage. At each visit acne severity, photos, side effects, and patient-reported satisfaction were recorded.ResultsIn the two groups, no significant difference in reduction of lesion count and Global Acne Grading System scores. The frequency of treatment-related side effects was (20%) in Group A and (76.7%) in Group B. Furthermore, there was no difference regarding the relapse rates between both groups (p>0.05). Finally, the patients’ satisfaction rates did not differ between the two groups.ConclusionOral zinc plus low-dose isotretinoin resulted in satisfactory improvement in AV patients with fewer side effects. Further studies are recommended to compare the efficacy of other zinc preparations if combined with systemic isotretinoin at different concentrations.     

达英-35加面部护理治疗痤疮疗效观察

目的 探讨面部护理加服达英－３５治疗痤疮的疗效。方法 采用面部护理治疗的同时按月经周期服用达英－３５的方法对５６例痤疮的患者进行系统性治疗２个月,并与单纯面部护理及单纯口服达英－３５进行对照。结果 混合组治愈率达８５％,总有效率１００％,较单纯面部护理有显著性差异,与单纯口服达英－３５组无显著性差异,但有显著性差异的趋势。结论 在单纯面部护理基础上服用达英－３５可以提高疗效,并可减少痤疮后遗症。     

Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol

OBJECTIVES: Poor cycle control and tolerability can be reasons for irregular pill intake. This study compared the tolerability of two low-dose oral contraceptives and their effect on cycle control. METHODS: In this open, group-comparative, randomized multicenter trial in Germany and the Netherlands, women received either 20 microg ethinylestradiol plus 150 microg desogestrel (20EE/DSG; n = 500) or 20 microg ethinylestradiol plus 100 microg levonorgestrel (20EE/LNG; n = 498) for six treatment cycles. Cycle control, dysmenorrhea and premenstrual syndrome (PMS) were assessed using diary cards. Tolerability was assessed using the self-administered questionnaires Psychological General Well-Being Index (PGWBI) and the Profile of Mood States (POMS). Acne was assessed by objective (acne counts) and subjective (no, moderate, mild, severe) acne scoring of the facial area at baseline and treatment cycles 1, 3 and 6. RESULTS: A total of 404 (78.1%) and 384 (75.3%) women in the 20EE/DSG and 20EE/LNG groups, respectively, completed the trial. The occurrence rate of irregular bleeding and spotting was statistically significantly higher with 20EE/LNG than with 20EE/DSG (0.18 vs. 0.13; p < 0.05). The mean number of bleeding-spotting days per cycle was statistically significantly higher with 20EE/LNG than with 20EE/DSG (0.63 vs. 0.48; p < 0.05). Early withdrawal bleeding was more frequent with 20EE/LNG (0.15 vs. 0.08; p < 0.005), whereas continued withdrawal bleeding was more frequent with 20EE/DSG (0.32 vs. 0.45; p < 0.001); absence of withdrawal bleeding was comparable (0.06 vs. 0.04, respectively). Thirteen subjects in the 20EE/LNG group and three in the 20EE/DSG group discontinued due to unacceptable bleeding (p < 0.05). Dysmenorrhea and PMS decreased comparably in both groups. There were no differences between groups for the mean total scores of PGWBI or POMS at all time-points. Fewer acne lesions were counted with 20EE/DSG vs. 20EE/LNG after six cycles (p < 0.05). The subjective acne scores supported this finding. CONCLUSIONS: 20EE/DSG provided better cycle control than 20EE/LNG with less treatment discontinuation due to unacceptable bleeding. There were no apparent differences between the two groups regarding tolerability and quality of life. There was less acne with 20EE/DSG.